Unicycive Therapeutics has hit a bump on the road in its mission to bring its hyperphosphatemia treatment candidate to ...

FDA issues a complete response letter for oxylanthanum carbonate, a treatment for hyperphosphatemia in patients with chronic ...

In the United States alone, about 1 in 10 adults use these drugs regularly. Some well-known brands include Prilosec, Nexium, ...

FDA denies Unicycive's NDA for Oxylanthanum Carbonate due to vendor issues; company eyes quick resolution with alternate ...

Ardelyx's IBSRELA shows strong 57% sales growth, but faces stiff competition and uncertain sustainability. Click here to read ...

Unicycive, which was seeking approval of oxylanthanum carbonate to treat hyperphosphatemia in patients with chronic kidney disease on dialysis, said the FDA issued a so-called complete response letter ...

Unicycive had submitted the New Drug Application for OLC to treat hyperphosphatemia in patients with chronic kidney disease on dialysis. The company emphasized that the FDA has not highlighted any ...

Phosphate binders are often prescribed with meals for people with kidney disease to reduce the uptake of phosphate in food.

Altimmune shares cratered more than 50% on Thursday after its experimental obesity drug did not significantly improve liver ...